Drug development and the cellular quality control system

被引:48
作者
Conn, P. Michael [1 ]
Janovick, Jo Ann
机构
[1] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA
基金
美国国家卫生研究院;
关键词
NEPHROGENIC DIABETES-INSIPIDUS; COUPLED RECEPTOR TRAFFICKING; TRANSMEMBRANE CONDUCTANCE REGULATOR; PLASMA-MEMBRANE EXPRESSION; DELTA-OPIOID RECEPTOR; HORMONE RECEPTOR; PHARMACOLOGICAL CHAPERONES; ENDOPLASMIC-RETICULUM; HYPOGONADOTROPIC HYPOGONADISM; CYSTIC-FIBROSIS;
D O I
10.1016/j.tips.2009.02.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteins serve in cellular roles that necessitate structural precision, a requirement overseen by the cellular quality control system (QCS). By rejecting misfolded proteins, the QCS protects against aberrant activity. Misfolding and subsequent retention by the QCS results in proteins that might maintain function but become misrouted and cause disease. Correcting the misrouting of misfolded mutant proteins often restores activity and addresses the underlying disease. Because of its small size, the gonadotropin-releasing hormone receptor has been an excellent model for G-protein-coupled receptor trafficking and has recently enabled elucidation of both the requirements to pass the QCS and the biochemical mechanism of rescue by pharmacological chaperones; this information will now enable rational design of these therapeutic agents. Here, we summarize what is known about the relation between receptor structure and interactions with the QCS with a view toward therapeutic development based on the rescue of misfolded and, consequently, misrouted mutants with drugs.
引用
收藏
页码:228 / 233
页数:6
相关论文
共 63 条
[1]   Therapy through chaperones: Sense or antisense? - Cystic fibrosis as a model disease [J].
Amaral, MD .
JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (2-3) :477-487
[2]   Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail [J].
Andersson, H ;
D'Antona, AM ;
Kendall, DA ;
Von Heijne, G ;
Chin, CN .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :570-577
[3]   Theoretical and experimental basis for the inhibition of cataract [J].
Benedek, GB ;
Pande, J ;
Thurston, GM ;
Clark, JI .
PROGRESS IN RETINAL AND EYE RESEARCH, 1999, 18 (03) :391-402
[4]   Pharmacological chaperone action on G-protein-coupled receptors [J].
Bernier, V ;
Bichet, DG ;
Bouvier, M .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) :528-533
[5]   Pharmacological chaperones:: potential treatment for conformational diseases [J].
Bernier, V ;
Lagacé, M ;
Bichet, DG ;
Bouvier, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (05) :222-228
[6]   Nephrogenic diabetes insipidus [J].
Bichet, DG .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2006, 13 (02) :96-104
[7]   Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: Molecular basis of the dominant-negative effect [J].
Brothers, SP ;
Cornea, A ;
Janovick, JA ;
Conn, PM .
MOLECULAR ENDOCRINOLOGY, 2004, 18 (07) :1787-1797
[8]   Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z:: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency [J].
Burrows, JAJ ;
Willis, LK ;
Perlmutter, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1796-1801
[9]   Beyond the signal sequence:: Protein routing in health and disease [J].
Castro-Fernández, C ;
Maya-Núñez, G ;
Conn, PM .
ENDOCRINE REVIEWS, 2005, 26 (04) :479-503
[10]   Protein misfolding, functional amyloid, and human disease [J].
Chiti, Fabrizio ;
Dobson, Christopher M. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :333-366